Monte Rosa Therapeutics (GLUE) earnings
In the quarter ended June 2026, Monte Rosa Therapeutics had revenue of $9M, down 61.3% on a year earlier.
On August 6, 2026 it reported EPS of -0.43 against an estimate of -0.25 (missed).
The next report is expected on Thursday, November 5, 2026, with EPS expected around -0.10.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Thu Nov 5, 2026 | — | -0.10 | — |
| Last | Thu Aug 6, 2026 | — | -0.25 | -0.43 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Monte Rosa Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $9M | -61.3% | — | — | -547.8% | 2026-08-06 |
| Mar 31, 2026 | $4M | -95.0% | — | — | -1188.5% | 2026-05-07 |
| Dec 31, 2025 | $3M | -95.4% | — | — | -1787.7% | 2026-03-17 |
| Sep 30, 2025 | $13M | +38.5% | — | — | -258.3% | 2025-11-06 |
| Jun 30, 2025 | $23M | +394.0% | — | — | -67.1% | 2025-08-07 |
| Mar 31, 2025 | $85M | +7882.0% | — | — | 51.9% | 2025-05-08 |
| Dec 31, 2024 | $61M | — | — | — | 21.4% | 2025-03-20 |
| Sep 30, 2024 | $9M | — | — | — | -287.8% | 2024-11-07 |
| Jun 30, 2024 | $5M | — | — | — | -695.3% | 2024-08-08 |
| Mar 31, 2024 | $1M | — | — | — | -3284.5% | 2024-05-09 |
| Dec 31, 2023 | $0 | — | — | — | — | 2024-03-14 |
| Sep 30, 2023 | $0 | — | — | — | — | 2023-11-09 |
Questions
When does Monte Rosa Therapeutics report earnings?
Monte Rosa Therapeutics's next earnings report is expected on November 5, 2026.
How did Monte Rosa Therapeutics do last quarter?
In the quarter ended June 2026, Monte Rosa Therapeutics had revenue of $9M, down 61.3% on a year earlier.
From Monte Rosa Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.